Fulgent Genetics Inc. reported another quarter of record revenue as it continued to ride the Covid testing wave.
Alhambra-based Apollo Medical Holdings Inc. has reaped considerable profit by managing administrative and back-office functions for physician groups.
Shares of biotech firm Capricor Inc. surged April 29 following the announcement that it has a licensing deal with Johns Hopkins University.
Santa Monica-based GoodRx Holdings Inc. has acquired New York-based HealthiNation Inc., the operator of an online health care video library.
MedTech Innovator, a Westwood-based nonprofit that operates accelerators for medical companies, has launched a new biotech accelerator program.
Santa Monica-based Quantgene Inc. has formed a partnership with San Diego-based cancer therapy guidance company CureMatch Inc.
Duarte-based City of Hope is extending its reach to South America.
Venice-based microbial sciences company Seed Health Inc. has closed a $40 million financing round.
Long Beach-based Agilon Health Inc. raised approximately $1.07 billion through its initial public offering.
Culver City-based NantHealth Inc. announced a $137 million financing package that will be provided by two of its existing investors.
Long Beach-based Agilon Health Inc., which helps primary care physician groups to cap costs for their Medicare Advantage patients, is seeking to raise up to $1.7 billion from its IPO.
City of Hope Researcher Arthur Riggs Helped Create Artificial Insulin, Now Emerges as Its Largest Donor
Arthur Riggs, a pioneer of the modern biotech industry and developer of artificial insulin has donated over $300 million to City of Hope.
Long Beach-based Agilon Health Inc., which helps primary care physician groups cap costs for their Medicare Advantage patients, filed paperwork on March 18 with the Securities and Exchange Commission to become a publicly traded company.
USC has selected University of Pittsburgh Medical Center executive Steven Shapiro to fill a newly created role to guide the school’s health sciences programs starting May 15.
Santa Monica-based Kite Pharma announced March 5 that the Food and Drug Administration has granted accelerated approval for the company’s principal drug, Yescarta, for the treatment of adult patients with relapsed follicular lymphoma after two or more other therapies had already been applied.